Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to $13.6 million.

  • Rockwell Medical's Cash & Equivalents rose 1030.96% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 1030.96%. This contributed to the annual value of $15.7 million for FY2024, which is 7435.16% up from last year.
  • As of Q3 2025, Rockwell Medical's Cash & Equivalents stood at $13.6 million, which was up 1030.96% from $12.5 million recorded in Q2 2025.
  • Rockwell Medical's 5-year Cash & Equivalents high stood at $35.7 million for Q1 2021, and its period low was $6.6 million during Q1 2024.
  • Over the past 5 years, Rockwell Medical's median Cash & Equivalents value was $12.3 million (recorded in 2024), while the average stood at $15.2 million.
  • In the last 5 years, Rockwell Medical's Cash & Equivalents crashed by 7272.09% in 2021 and then surged by 7435.16% in 2024.
  • Quarter analysis of 5 years shows Rockwell Medical's Cash & Equivalents stood at $13.3 million in 2021, then dropped by 23.93% to $10.1 million in 2022, then dropped by 11.08% to $9.0 million in 2023, then soared by 74.35% to $15.7 million in 2024, then dropped by 13.1% to $13.6 million in 2025.
  • Its Cash & Equivalents stands at $13.6 million for Q3 2025, versus $12.5 million for Q2 2025 and $11.4 million for Q1 2025.